"Janus Kinase 1" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A Janus kinase subtype that is involved in signaling from a broad variety of CYTOKINE RECEPTORS.
| Descriptor ID |
D053613
|
| MeSH Number(s) |
D08.811.913.696.620.682.725.124.100 D12.776.476.393.100
|
| Concept/Terms |
Janus Kinase 1- Janus Kinase 1
- JAK-1 Protein Tyrosine Kinase
- JAK 1 Protein Tyrosine Kinase
- JAK1 Protein Tyrosine Kinase
- Jak1 Kinase
|
Below are MeSH descriptors whose meaning is more general than "Janus Kinase 1".
Below are MeSH descriptors whose meaning is more specific than "Janus Kinase 1".
This graph shows the total number of publications written about "Janus Kinase 1" by people in this website by year, and whether "Janus Kinase 1" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2004 | 0 | 1 | 1 |
| 2006 | 0 | 1 | 1 |
| 2007 | 2 | 0 | 2 |
| 2012 | 1 | 0 | 1 |
| 2015 | 1 | 0 | 1 |
| 2018 | 1 | 0 | 1 |
| 2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Janus Kinase 1" by people in Profiles.
-
Shrestha H, R?dler PD, Dennaoui R, Wicker MN, Rajbhandari N, Sun Y, Peck AR, Vistisen K, Triplett AA, Beydoun R, Sterneck E, Saur D, Rui H, Wagner KU. The Janus kinase 1 is critical for pancreatic cancer initiation and progression. Cell Rep. 2024 May 28; 43(5):114202.
-
Hurwitz H, Van Cutsem E, Bendell J, Hidalgo M, Li CP, Salvo MG, Macarulla T, Sahai V, Sama A, Greeno E, Yu KH, Verslype C, Dawkins F, Walker C, Clark J, O'Reilly EM. Ruxolitinib + capecitabine in advanced/metastatic pancreatic cancer after disease progression/intolerance to first-line therapy: JANUS 1 and 2 randomized phase III studies. Invest New Drugs. 2018 08; 36(4):683-695.
-
Shanavas M, Popat U, Michaelis LC, Fauble V, McLornan D, Klisovic R, Mascarenhas J, Tamari R, Arcasoy MO, Davies J, Gergis U, Ukaegbu OC, Kamble RT, Storring JM, Majhail NS, Romee R, Verstovsek S, Pagliuca A, Vasu S, Ernst B, Atenafu EG, Hanif A, Champlin R, Hari P, Gupta V. Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors. Biol Blood Marrow Transplant. 2016 Mar; 22(3):432-40.
-
Podolsky MA, Solomos AC, Durso LC, Evans SM, Rall GF, Rose RW. Extended JAK activation and delayed STAT1 dephosphorylation contribute to the distinct signaling profile of CNS neurons exposed to interferon-gamma. J Neuroimmunol. 2012 Oct 15; 251(1-2):33-8.
-
Neilson LM, Zhu J, Xie J, Malabarba MG, Sakamoto K, Wagner KU, Kirken RA, Rui H. Coactivation of janus tyrosine kinase (Jak)1 positively modulates prolactin-Jak2 signaling in breast cancer: recruitment of ERK and signal transducer and activator of transcription (Stat)3 and enhancement of Akt and Stat5a/b pathways. Mol Endocrinol. 2007 Sep; 21(9):2218-32.
-
Capriotti LA, Beebe TP, Schneider JP. Hydroxyapatite surface-induced peptide folding. J Am Chem Soc. 2007 Apr 25; 129(16):5281-7.
-
Jasmin JF, Mercier I, Sotgia F, Lisanti MP. SOCS proteins and caveolin-1 as negative regulators of endocrine signaling. Trends Endocrinol Metab. 2006 May-Jun; 17(4):150-8.
-
Tliba O, Panettieri RA, Tliba S, Walseth TF, Amrani Y. Tumor necrosis factor-alpha differentially regulates the expression of proinflammatory genes in human airway smooth muscle cells by activation of interferon-beta-dependent CD38 pathway. Mol Pharmacol. 2004 Aug; 66(2):322-9.